Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model

INTRODUCTION: Risankizumab has demonstrated efficacy in treating moderate-to-severe psoriasis. The phase-3 IMMhance trial (NCT02672852) examined the effect of continuing versus withdrawing from risankizumab treatment on psoriasis severity, including the Psoriasis Area and Severity Index (PASI) and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, Kim A., Soliman, Ahmed M., Done, Nicolae, Carley, Christopher, Lemus Wirtz, Esteban, Puig, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322223/
https://www.ncbi.nlm.nih.gov/pubmed/34019229
http://dx.doi.org/10.1007/s13555-021-00550-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322223/
https://www.ncbi.nlm.nih.gov/pubmed/34019229
http://dx.doi.org/10.1007/s13555-021-00550-8

Ejemplares similares